Pancreatic Cancer Prognosis and Treatment

Overall Survival Statistics

• Pancreatic cancer ranks as the fourth most common cause of cancer death worldwide, with mortality rates closely matching incidence rates 1, 2
• The American Society of Clinical Oncology notes that pancreatic cancer has an extremely poor prognosis with an overall 5-year survival rate of less than 5%, making it one of the deadliest forms of cancer 1, 2, 3

Prognosis by Disease Stage

Resectable Disease (Early Stage)

• Only 10-20% of patients are diagnosed with surgically resectable disease 1
• Adjuvant chemotherapy more than doubles the 5-year survival rate from 10% with surgery alone to 25% with postoperative chemotherapy, according to the European Society for Medical Oncology 3

Advanced Disease

• 50-60% of patients present with metastatic disease at diagnosis 2, 3
• The National Comprehensive Cancer Network states that gemcitabine has been the standard chemotherapy for over a decade, with newer combination regimens showing modest improvements 3

Important Caveats

• Despite improvements in surgical techniques and chemotherapy protocols, pancreatic cancer remains overwhelmingly fatal, as noted by the American Cancer Society 1, 2

Pankreas Kanseri Yaşam Beklentisi

Genel Bilgiler

• Pankreas kanseri, %95'ten fazla hastanın hastalıklarından dolayı öldüğü, son derece ölümcül bir kanserdir ve tanı anında metastatik hastalığın yüksek insidansı nedeniyle mortalite oranı yüksektir 4

Tedavi ve Sağkalım

• Tam cerrahi rezeksiyon, potansiyel olarak küratif tek tedavidir, ancak 5 yıllık genel sağkalım sadece %10-20'dir 5, 6, 7, 8
• N+ tümörlerde (lenf nodu pozitif) uzun süreli sağkalım nadirdir 5, 6, 7, 8
• Hastaların %20'sinden azında rezekte edilebilir hastalık vardır 5, 6, 7, 8
• Metastatik hastalığın yönetiminde optimal semptomatik tedavi önemli bir role sahiptir 5, 6, 7, 8

Hastalık Insidansı ve Prognoz

• Pankreas kanseri tanısı alan hastaların çoğu (%80-85) ileri evre hastalıkla başvurur ve cerrahi rezeksiyon seçeneği yoktur 9

Life Expectancy and Management of Stage 1-B Pancreatic Cancer

Monitoring and Follow-up

• Evaluation of response should be symptom-driven rather than solely relying on imaging, as recommended by the European Society for Medical Oncology, in patients with pancreatic cancer 10
• Regular monitoring for recurrence is essential as most patients will eventually experience disease progression, according to the European Society for Medical Oncology 10, 11

Life Expectancy in Metastatic Pancreatic Cancer with Liver Involvement

Overview of Survival

• For patients with pancreatic adenocarcinoma and liver metastases, median survival without chemotherapy is approximately 1.3-3.4 months, while combination chemotherapy extends this to 6-11 months depending on performance status and regimen used 12
• The 5-year survival rate for metastatic pancreatic cancer remains at 2% overall, though this includes treated patients 12

Chemotherapy Benefits

• Chemotherapy significantly extends survival, with outcomes dependent on performance status and regimen selection, providing a median survival of 6-11 months 12
• For fit patients, first-line combination regimens such as FOLFIRINOX or gemcitabine plus nab-paclitaxel provide a survival benefit of 2-6 months compared to single-agent gemcitabine 12

Palliative Care

• Palliative care referral should occur at the first visit, not delayed until end-stage disease, as recommended by the American Society of Clinical Oncology 12

Treatment Considerations

• Patients with poor performance status should only be offered cancer-directed therapy case-by-case, with emphasis on supportive care, as suggested by the National Comprehensive Cancer Network 12
• Goals of care discussions must occur early, including advance directives and patient preferences, to guide treatment intensity decisions 12